Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (Dec 2019)

The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA‐Q)

  • Sylvie Belleville,
  • Andréa C. LeBlanc,
  • Marie‐Jeanne Kergoat,
  • Frédéric Calon,
  • Pierrette Gaudreau,
  • Sébastien S. Hébert,
  • Carol Hudon,
  • Nicole Leclerc,
  • Naguib Mechawar,
  • Simon Duchesne,
  • Serge Gauthier,
  • Consortium for the Early Identification of Alzheimer's disease‐Quebec (CIMA‐Q),
  • Pierre Bellec,
  • Sylvie Belleville,
  • Christian Bocti,
  • Frédéric Calon,
  • Howard Chertkow,
  • Louis Collins,
  • Stephen Cunnane,
  • Simon Duchesne,
  • Pierrette Gaudreau,
  • Serge Gauthier,
  • Sébastien S. Hébert,
  • Carol Hudon Marie‐Jeanne‐Kergoat,
  • Andréa C. LeBlanc,
  • Nicole Leclerc,
  • Naguib Mechawar,
  • Natalie Philips,
  • Jean‐Paul Soucy,
  • Thien Thanh Dang Vu,
  • Louis Verret,
  • Juan Manuel Villalpando

DOI
https://doi.org/10.1016/j.dadm.2019.07.003
Journal volume & issue
Vol. 11, no. 1
pp. 787 – 796

Abstract

Read online

Abstract Introduction The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA‐Q) created a research infrastructure to recruit, characterize, and track disease progression in individuals at risk of dementia. Methods CIMA‐Q established standardized clinical, neuropsychological, neuroimaging, blood (plasma, serum, RNA, genomic DNA), cryopreserved peripheral blood mononuclear cells, and cerebrospinal fluid collection protocols. These data and biological materials are available to the research community. Results In phase 1, 115 persons with subjective cognitive decline, 88 with mild cognitive impairment, 31 with early probable Alzheimer's disease, and 56 older adults with no worries nor impairments received detailed clinical and cognitive evaluations as well as blood and peripheral blood mononuclear cells collections. Among them, 142 underwent magnetic resonance imaging, 29 a 18fluorodeoxyglucose positron emission tomography, and 60 a lumbar puncture. Discussion CIMA‐Q provides procedures and resources to identify early biomarkers and novel therapeutic targets, and holds promise for detecting cognitive decline in Alzheimer's disease.

Keywords